Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2140011 | Leukemia Research | 2006 | 4 Pages |
Abstract
Digitoxin is used in the treatment of cardiac congestion and some types of cardiac arrhythmias. The mechanism of action of this cardiac glycoside suggested that it might antagonize the anticancer activity of topoisomerase II poisons. The present report shows that digitoxin, at concentrations commonly found in the plasma of cardiac patients, significantly reduced etoposide and idarubicin-induced topoisomerase II cleavable complexes in K562 leukemia cells. This may lead to a reduction in the anticancer effect of these two topoisomerase II poisons when they are used in the clinic concurrently with digitoxin.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Miguel López-Lázaro, Nuria Pastor, Sami S. Azrak, Maria Jesús Ayuso, Felipe Cortés, Caroline A. Austin,